IT Site Traffic Growth Resilient Despite AI Search Roll Out 
ESW Launches GovCon Accelerator™: A First-of-Its-Kind Framework for Secure, Compliance-Driven Microsoft 365 Deployments in GCC High 
Indonesia’s Legacy in the Global Vaccine Landscape: Bio Farma and DCVMN Strengthen Health Resilience through Global Partnership AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti
These new appointments bring extensive US and international experience in company leadership and development of…
AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti
These new appointments bring extensive US and international experience in company leadership and development of…
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic…
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic…
Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
Keros Therapeutics announces U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug…
Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
Keros Therapeutics announces U.S. Food and Drug Administration (“FDA”) has cleared its investigational new drug…
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma…
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma…
Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results
BEDFORD, Mass., July 24, 2023 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused…
Ocular Therapeutix™ To Report Second Quarter 2023 Financial Results
BEDFORD, Mass., July 24, 2023 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused…
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
REDWOOD CITY, Calif., July 24, 2023 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
REDWOOD CITY, Calif., July 24, 2023 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a…
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful results These…
PaxMedica Announces Positive Top Line Results from the PAX-101 (intravenous suramin) Phase 3 African Sleeping Sickness Study, PAX-HAT-301
The study’s primary endpoint was reached and demonstrated statistically significant and clinically meaningful results These…
QIAGEN N.V. to release results for Q2 2023 and hold webcast
Venlo, The Netherlands, July 24, 2023 (GLOBE NEWSWIRE) — QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock…
QIAGEN N.V. to release results for Q2 2023 and hold webcast
Venlo, The Netherlands, July 24, 2023 (GLOBE NEWSWIRE) — QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock…
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement…
Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement…
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) — Overland ADCT…
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) — Overland ADCT…